Financial Performance - The company's operating revenue for the current period is CNY 1,078,407,914.14, representing a 24.22% increase compared to the same period last year[2]. - The net profit attributable to shareholders for the current period is CNY 300,022,177.20, reflecting a 37.87% increase year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 292,408,573.13, which is a 42.99% increase compared to the same period last year[2]. - The basic earnings per share for the current period is CNY 0.33, up 37.50% year-over-year[2]. - The diluted earnings per share for the current period is also CNY 0.33, reflecting a 37.50% increase compared to the same period last year[2]. - The total revenue for the third quarter was RMB 299,848.69 million, with a year-on-year increase of 13.96% compared to RMB 263,116.51 million in the same period last year[44]. - The total revenue from sales of goods and services reached ¥3,203,765,796.39, an increase from ¥2,830,297,051.04 in the previous period, reflecting a growth of approximately 13.2%[51]. - Net profit for the current period was ¥816,207,101.19, representing a growth of 8.83% from ¥749,960,735.73 in the previous period[56]. - The company reported a total profit of ¥982,201,017.90, up from ¥874,864,345.00 in the previous period, reflecting a growth of 12.29%[56]. Assets and Liabilities - The total assets at the end of the current period amount to CNY 8,392,332,820.84, showing an 8.70% increase from the end of the previous year[2]. - The equity attributable to shareholders at the end of the current period is CNY 7,583,191,255.85, which is a 9.87% increase compared to the end of the previous year[2]. - The company's non-current assets totaled RMB 3,273,593,297.36, with total assets amounting to RMB 8,392,332,820.84 as of September 30, 2023[35]. - The total liabilities amounted to ¥796,751,228.87, a decrease from ¥813,851,345.77 in the previous period, showing a reduction of approximately 2.5%[51]. - The company's total non-current liabilities decreased to ¥79,786,515.49 from ¥120,191,379.00, indicating a reduction of about 33.6%[51]. Cash Flow and Investments - The net cash flow from operating activities was ¥1,005,804,614.23, compared to ¥814,185,488.67 in the same period last year, indicating a year-over-year increase of about 23.5%[51]. - The cash flow from investment activities showed a net outflow of ¥1,951,455,806.19, an improvement from a net outflow of ¥2,111,012,654.23 in the previous year[51]. - The cash received from investment recoveries was ¥2,706,570,000.00, down from ¥3,740,800,000.00, reflecting a decrease of approximately 27.7%[51]. - The net cash flow from financing activities was -¥130,346,613.38, compared to -¥73,652,731.77 in the previous period, indicating increased cash outflow[58]. Research and Development - Research and development expenses were ¥258,348,158.90, an increase of 10.09% from ¥234,691,455.70 in the previous period[8]. Market and Growth Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[36]. - The company has not disclosed any significant mergers or acquisitions in the recent quarter[36]. Other Financial Metrics - The weighted average return on equity for the current period is 4.05%, a slight increase of 0.78% compared to the previous year[2]. - The company reported a significant increase in other payables, which rose to ¥268,344,909.64 from ¥65,829,631.01, marking an increase of approximately 307.5%[51]. - The company's cash and cash equivalents decreased to RMB 2,526,863,956.33 from RMB 3,585,368,804.77, representing a decline of about 30%[35]. - The inventory increased to RMB 377,072,129.86 from RMB 330,963,949.25, indicating a growth of approximately 14%[35]. - The company experienced a foreign exchange impact of ¥7,491.70 on cash and cash equivalents[58].
康弘药业(002773) - 2023 Q3 - 季度财报